Eisai Clinical Trials
Study Overview
E7080
lenvatinib
NCT01321554, JapicCTI-111573, jRCT2080221533, 2010-023783-41
Mar 2011 - Mar 2019
Thyroid Cancer
1. Progression Free Survival (PFS) [Time Frame: Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years]
-
Males and females 18 Years and older (Adult, Older Adult)
-
Completed -
Phase 3
Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Thailand, United Kingdom, United States See moreData Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
CSDR Sharing is available for this study.
CSDR Availability Clinical Trial Data Redacted documents may be available upon request for this study.
Document type Availability Protocol SAP Sample CRF Full CSR